178 related articles for article (PubMed ID: 1672872)
1. c-erbB-2 expression in different histological types of invasive breast carcinoma.
Soomro S; Shousha S; Taylor P; Shepard HM; Feldmann M
J Clin Pathol; 1991 Mar; 44(3):211-4. PubMed ID: 1672872
[TBL] [Abstract][Full Text] [Related]
2. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
Somerville JE; Clarke LA; Biggart JD
J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast.
Maguire HC; Hellman ME; Greene MI; Yeh I
Pathobiology; 1992; 60(3):117-21. PubMed ID: 1352687
[TBL] [Abstract][Full Text] [Related]
5. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
[TBL] [Abstract][Full Text] [Related]
6. c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study.
Soomro S; Taylor P; Shepard HM; Feldmann M; Sinnett HD; Shousha S
Int J Cancer; 1993 Aug; 55(1):63-5. PubMed ID: 8102130
[TBL] [Abstract][Full Text] [Related]
7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.
Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S
Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
[TBL] [Abstract][Full Text] [Related]
10. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2 expression in benign and malignant breast disease.
Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Elliott C; Ashley S; Monaghan P; Harrison S
Br J Cancer; 1988 Oct; 58(4):453-7. PubMed ID: 2849975
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
13. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
[TBL] [Abstract][Full Text] [Related]
14. Classification and grading of invasive breast carcinoma.
Elston CW
Verh Dtsch Ges Pathol; 2005; 89():35-44. PubMed ID: 18035670
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
16. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
Looi LM; Cheah PL; Yap SF
Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
[TBL] [Abstract][Full Text] [Related]
17. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
18. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
Tsuda H; Iwaya K; Fukutomi T; Hirohashi S
Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903
[TBL] [Abstract][Full Text] [Related]
20. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
